OncoMatch/Clinical Trials/NCT03079323

Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer

Is NCT03079323 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.

Phase 2RecruitingUniversitaire Ziekenhuizen KU LeuvenNCT03079323Data as of May 2026

Prospective non-randomized phase 2 trial to study the efficacy of additional elective para-aortic RT (PART) in pN1 patients compared to those who were historically treated with adjuvant whole pelvic radiotherapy (WPRT) alone.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Required: Stage PN1

Excluded: Stage CM1A, CM1B, CM1C

Presence of pN1 disease after ePLND (criteria defined in the protocol); Presence of cM1a, cM1b or cM1c disease [excluded]

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiotherapy

Exception: if makes WPRT and/or PART impossible

Former radiotherapy making WPRT and/or PART impossible

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify